EUR/USD Forecast: New week, better luck with cracking 1.20? Laying out the bullish case
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- EUR/USD has kicked off the week under 1.20 as US yields fall.
- Rising vaccination rates in Europe may boost the common currency.
- Monday's four-hour chart is painting a bullish picture.
Is the fifth attempt to break above 1.20 going to be different than the previous ones? That is the question for EUR/USD traders, who are battling over the round number. While the attention in Europe may be on the upcoming "Superleague" of football teams, currency markets may be ready for outsized moves after days of frustrating range trading.
The good news for the old continent is that the vaccination campaign has picked up and bottlenecks seem to have been removed. Nearly 25 doses have been given per person – or nearly 20% have received at least one shot.
Source: FT
The EU will receive 50 million additional Pfizer/BioNTech doses in the second quarter and the issues with Johnson & Johnson's single-shot inoculations may be removed shortly. While the US FDA could drag its feet for weeks before releasing its verdict on J&J and links to blood clots, the European Medicines Agency promised updates this week. The US pharmaceutical is on course to deliver 55 million doses through June– covering the same amount of people – if it gets the green light.
The faster vaccination rhythm is far from being priced into the euro.
On the other side of the pond, 40% of Americans have received at least one dose, but the upbeat pace was already factored in. More importantly for the dollar, bond yields are dropping, making the greenback less attractive. Returns on ten-year Treasuries are below 1.56% at the time of writing.
The dollar advanced thanks to the roaring back of America's economy, reflected in figures such as a 9.8% leap in retail sales last month. However, demand from the US consumer has ripple effects and may also boost the European economies. In the nearer term, such a "risk-on" mood is positive for the currency pair.
One source of worry is the political impasse in Germany's ruling CDU/CSU bloc. Armin Laschet and Markus Söder have been clashing on who replace Chancellor Angela Merkel as chancellor candidate. However, a quick resolution is likely as early as Monday.
All in all, fundamentals point to a growing chance that EUR/USD bursts above 1.20.
EUR/USD Technical Analysis
Euro/dollar is benefiting from upside momentum on the four-hour chart and trades above the 50, 100 and 200 Simple Moving Averages – all bullish signs. Moreover, the currency pair exited overbought conditions.
Overall, bulls are in control.
Above the critical 1.20 level, the next levels to watch date to March and February, and include 1.2025, 1.2065 and 1.2115.
Support awaits at the daily low of 1.1945, followed by 1.1925 and 1.1860, which accompanied the pair during its recent ascent.
The pause that refreshes: Are currency markets hesitant to run with US data?
- EUR/USD has kicked off the week under 1.20 as US yields fall.
- Rising vaccination rates in Europe may boost the common currency.
- Monday's four-hour chart is painting a bullish picture.
Is the fifth attempt to break above 1.20 going to be different than the previous ones? That is the question for EUR/USD traders, who are battling over the round number. While the attention in Europe may be on the upcoming "Superleague" of football teams, currency markets may be ready for outsized moves after days of frustrating range trading.
The good news for the old continent is that the vaccination campaign has picked up and bottlenecks seem to have been removed. Nearly 25 doses have been given per person – or nearly 20% have received at least one shot.
Source: FT
The EU will receive 50 million additional Pfizer/BioNTech doses in the second quarter and the issues with Johnson & Johnson's single-shot inoculations may be removed shortly. While the US FDA could drag its feet for weeks before releasing its verdict on J&J and links to blood clots, the European Medicines Agency promised updates this week. The US pharmaceutical is on course to deliver 55 million doses through June– covering the same amount of people – if it gets the green light.
The faster vaccination rhythm is far from being priced into the euro.
On the other side of the pond, 40% of Americans have received at least one dose, but the upbeat pace was already factored in. More importantly for the dollar, bond yields are dropping, making the greenback less attractive. Returns on ten-year Treasuries are below 1.56% at the time of writing.
The dollar advanced thanks to the roaring back of America's economy, reflected in figures such as a 9.8% leap in retail sales last month. However, demand from the US consumer has ripple effects and may also boost the European economies. In the nearer term, such a "risk-on" mood is positive for the currency pair.
One source of worry is the political impasse in Germany's ruling CDU/CSU bloc. Armin Laschet and Markus Söder have been clashing on who replace Chancellor Angela Merkel as chancellor candidate. However, a quick resolution is likely as early as Monday.
All in all, fundamentals point to a growing chance that EUR/USD bursts above 1.20.
EUR/USD Technical Analysis
Euro/dollar is benefiting from upside momentum on the four-hour chart and trades above the 50, 100 and 200 Simple Moving Averages – all bullish signs. Moreover, the currency pair exited overbought conditions.
Overall, bulls are in control.
Above the critical 1.20 level, the next levels to watch date to March and February, and include 1.2025, 1.2065 and 1.2115.
Support awaits at the daily low of 1.1945, followed by 1.1925 and 1.1860, which accompanied the pair during its recent ascent.
The pause that refreshes: Are currency markets hesitant to run with US data?
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.